Home Beauty Health The FDA’s weak drug manufacturing oversight is a potentially deadly problem: COVID-19 has exacerbated a backlog of domestic and foreign drug manufacturing inspections that the FDA is still too short-staffed to adequately deal with.

on July 26, 2021
The FDA’s weak drug manufacturing oversight is a potentially deadly problem: COVID-19 has exacerbated a backlog of domestic and foreign drug manufacturing inspections that the FDA is still too short-staffed to adequately deal with. submitted by /u/shallah
[link] [comments]


from Health https://ift.tt/3iPeOjq
,
Share To:

Unknown

View Profile

Post A Comment:

0 comments so far,add yours

Subscribe to: Post Comments (Atom)